Background: E-cadherin and β-catenin are adhesion molecules that promote integrity and stability of the urothelium. A decrease in their expression is associated with more aggressive tumour phenotypes with the ability to invade and metastasize. Material and Methods: 45 ICR male mice were used, of which 25 received N-butyl-N-(4-hydroxybutyl)nitrosamine (0.05%) in drinking water for a period of 12 weeks. Immunohistochemical expression was evaluated in all urinary bladder preparations for E-cadherin and for β-catenin. Results: Preneoplastic lesions showed staining patterns similar to normal urothelium. In simple and nodular hyperplasia, membrane staining was dominant (66.7-78.6 and 50-100%, respectively). In dysplasia a cytoplasmic pattern was prevalent (86.7-100%). Neoplastic lesions exhibit an abnormal staining pattern (100%) with heterogeneous staining (cytoplasmic, nuclear and membrane staining). A strong correlation was observed between both adhesion molecule staining patterns (r = 0.83; p = 0.039). Conclusions: In mice, as in humans, E-cadherin and β-catenin are valuable tools to investigate cellular adhesion status of urothelium and can be considered as indicators of tumour aggressiveness and evolution.

Keywords:
E-cadherin, β-catenin, Urothelium, Mice, N-butyl-N-(4-hydroxybutyl) nitrosamine
1.
Wijnhoven BP, Dinjens WN, Pignatelli M: E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87:992-1005.
2.
Guilford P: E-cadherin downregulation in cancer: fuel on the fire? Mol Med Today 1999;5:172-177.
3.
Beavon, IRG: The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000;36:1607-1620.
4.
Yagi T, Takeichi M: Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev 2000;14:1169-1180.
5.
Cavallaro U, Schaffhauser B, Christofori G: Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002;176:123-128.
6.
Sun W, Herrera GA: E-cadherin expression in invasive urothelial carcinoma. Ann Diagn Pathol 2004;8:17-22.
7.
Alberts B, Johnson A, Lewis J, et al: Molecular Biology of the Cell, ed 4. New York, Garland Science, 2002. Cell-Cell Adhesion. Available from: http://www.ncbi.nlm.nih.gov/books/NBK26937/.
8.
Lin Y, Sun G, Liu X, Chen Y, Zhang C: Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma. Urol Int 2011;86:340-345.
9.
Bryan R, Tselepis C: Cadherin switching and bladder cancer. J Urol 2010;184:423-431.
10.
Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE: The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 2007;26:85-110.
11.
Zhou YN, Xu CP, Han B0, Li M, Qiao L, Fang DC, Yang JM: Expression of E-cadherin and β-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol 2002;8:987-993.
12.
Cowin P, RowlandsTM, Hatsell SJ: Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005;17:499-508.
13.
Cook LM, Hursta DR, Welch DR: Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol 2011;21:113-122.
14.
Harington K, Syrigos K: The role of E-cadherin-catenin complex: more than an intercellular glue? Ann Surg Oncol 2000;7:783-788.
15.
Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z: E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int 2008;81:320-324.
16.
Keck B, Giedl J, Kunath F, Goebell PJ, Engehausen DG, Hartmann A, Wullich B: Clinical course of plasmacytoid urothelial carcinoma of the upper urinary tract: a case report? Urol Int 2012;89:120-122.
17.
Li D, Liu H, Yan L, Tang Y, Ren J, Xu Z: Lack of association between hOGG1 Ser326Cys polymorphism and the risk of bladder cancer: a meta-analysis. Urol Int 2012;88:88-94.
18.
Oliveira PA, Colaço A, De la Cruz LF, Lopes P, Lopes C: E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats. J Exp Clin Cancer Res 2006;25:425-432.
19.
Clevers H: Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-480.
20.
Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, Woodgett J, Winton DJ, Taketo MM, Wu XR, Leung HY, Sansom OJ: β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2011;30:178-198.
21.
Sakanaka C, Sun TQ, Williams LT: New steps in the Wnt/β-catenin signal transduction pathway. Recent Prog Horm Res 2000;55:225-236.
22.
Okegawa T, Li Y, Pong RC, Hsieh JT: Cell adhesion proteins as tumor suppressors. J Urol 2002;167:1836-1843.
23.
Grunwald GB: The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol 1993;5:797-805.
24.
Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): World Health Organization. Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004, pp 89-157.
25.
Serdar A, Turhan C, Soner G, Cem SN, Bayram K, Damla BE, Erbil E: The prognostic importance of E-cadherin and p53 gene expression in transitional bladder carcinoma patients. Int Urol Nephrol 2005;37:485-492.
26.
Garcia del Muro X, Torregrosa A, Muñoz J, Castellsagué X, Condom E, Vigués F, Arance A, Fabra A, Germà JR: Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. Eur J Cancer 2000;26:357-362.
27.
Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA, Hoznek A, Bastuji-Garin S, Abbou CC, Thiery JP, Radvanyi F, Chopin DK: Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 2000;83:209-214.
28.
Baumgart E, Cohen MS, Neto BS, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC: Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007;13:1685-1694.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.